EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

Long-Term Efficacy and Safety of Upacicalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism: Open-Label 52-Week Study

Takayuki Hamano, Fumihiko Koiwa, Yoshitaka Isaka, Keitaro Yokoyama, Masafumi Fukagawa, Yosuke Inagaki, Yukihisa S Watanabe, Daisuke Honda, Tadao Akizawa

American Journal of Nephrology · 2024

DOI: 10.1159/000541493 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Nephrology, 2024. Verfasst von Takayuki Hamano und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Renal Dialysis, Hyperparathyroidism, Secondary, Calcimimetic Agents, Kidney Failure, Chronic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Upacicalcet is a novel injectable calcimimetic. This phase 3 multicenter open-label study aimed to assess the long-term efficacy and safety of upacicalcet in hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT).

Methods

Japanese HD patients with serum intact parathyroid hormone (iPTH) levels >240 pg/mL and corrected calcium (cCa) levels ≥8.4 mg/dL were enrolled. Upacicalcet with a dose range of 25–300 µg was administered after each dialysis for 52 weeks. The main efficacy endpoint was the percentage of patients achieving the target iPTH level (60–240 pg/mL).

Results

A total of 157 patients were enrolled, of whom 138 completed the study. Overall, 94.2% of patients achieved the target serum iPTH level at week 52. Neither symptomatic hypocalcemia nor cCa level

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal DialysisHyperparathyroidism, SecondaryCalcimimetic AgentsKidney Failure, ChronicHumansFemaleMaleMiddle AgedAgedParathyroid HormoneCalciumTreatment OutcomeJapanFibroblast Growth Factor-23AdultPhosphatesPropionatesEast Asian People

Stichwörter der Autor:innen

CalcimimeticsCalciumGastrointestinal symptomsHypocalcemiaPhosphateUpacicalcet

Substanzen

Parathyroid HormoneCalciumCalcimimetic AgentsFibroblast Growth Factor-23PhosphatesupacicalcetPropionates

Autor:innen und Institutionen

  • Department of Nephrology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan.
  • Department of Nephrology, The University of Osaka Graduate School of Medicine, Suita, Japan.
  • Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
  • Division of Nephrology, Endocrinology, and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Shibuya, Japan.
  • Clinical Development Department, Sanwa Kagaku Kenkyusho Co., Ltd., Nagoya, Japan.

Zitieren

APA

Hamano, T., Koiwa, F., Isaka, Y., Yokoyama, K., Fukagawa, M., Inagaki, Y., Watanabe, Y. S., Honda, D., & Akizawa, T. (2024). Long-Term Efficacy and Safety of Upacicalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism: Open-Label 52-Week Study. American Journal of Nephrology. https://doi.org/10.1159/000541493

Vancouver

Hamano T, Koiwa F, Isaka Y, Yokoyama K, Fukagawa M, Inagaki Y, et al. Long-Term Efficacy and Safety of Upacicalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism: Open-Label 52-Week Study. American Journal of Nephrology. 2024. doi:10.1159/000541493

BibTeX
@article{Hamano2024,
  author = {Hamano, Takayuki and Koiwa, Fumihiko and Isaka, Yoshitaka and Yokoyama, Keitaro and Fukagawa, Masafumi and Inagaki, Yosuke and Watanabe, Yukihisa S and Honda, Daisuke and Akizawa, Tadao},
  title = {Long-Term Efficacy and Safety of Upacicalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism: Open-Label 52-Week Study},
  journal = {American Journal of Nephrology},
  year = {2024},
  doi = {10.1159/000541493}
}
Kostenlos starten →